(Total Views: 1315)
Posted On: 03/08/2017 7:37:17 PM
Post# of 15624
TEVA still has a $33 Billion dollar market Cap, and there was a good article written about them (basically they have gone down a bit because they have lost some patents (they really Need what OWCP has, 8 Patents)
From the articles:
It's not all bad news
The availability of a 40 mg generic Copaxone would undeniably be bad news for Teva Pharmacuetical in the short run. In early January, management conceded that a launch of a 40 mg generic in February could reduce revenue by $1 billion and non-GAAP EPS by $0.65 or more this year.
Undeniably, modeling for such a big hit to its financials following a launch demonstrates how significant the threat is to this company. However, Teva does still have opportunities that -- eventually -- could allow it to overcome headwinds tied to generic Copaxone.
For example, Teva Pharmaceutical can generate billions of dollars in revenue by developing complex biosimilars to expensive biologic drugs that are losing patent protection. It's also working on new brand-name drugs that have nine-figure (or better) potential, including therapies for big-value indications like chronic pain, migraine, and asthma.
Importantly, that innovation will happen against a backdrop of cost savings associated with the integration of Actavis' generic business, which Teva Pharmaceutical acquired last year. Teva thinks it can carve out $1.4 billion in synergies by 2019.
From the articles:
It's not all bad news
The availability of a 40 mg generic Copaxone would undeniably be bad news for Teva Pharmacuetical in the short run. In early January, management conceded that a launch of a 40 mg generic in February could reduce revenue by $1 billion and non-GAAP EPS by $0.65 or more this year.
Undeniably, modeling for such a big hit to its financials following a launch demonstrates how significant the threat is to this company. However, Teva does still have opportunities that -- eventually -- could allow it to overcome headwinds tied to generic Copaxone.
For example, Teva Pharmaceutical can generate billions of dollars in revenue by developing complex biosimilars to expensive biologic drugs that are losing patent protection. It's also working on new brand-name drugs that have nine-figure (or better) potential, including therapies for big-value indications like chronic pain, migraine, and asthma.
Importantly, that innovation will happen against a backdrop of cost savings associated with the integration of Actavis' generic business, which Teva Pharmaceutical acquired last year. Teva thinks it can carve out $1.4 billion in synergies by 2019.
(3)
(0)Scroll down for more posts ▼
